{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Defined as the percentage of patients with confirmed complete response, very good partial response, or partial response (CR, VGPR, or PR) according to International Myeloma Working Group Uniform Response Criteria. CR=bone marrow contains ≤5% plasma cells; negative fixation on serum and urine; disappearance of soft tissue plasmacytomas. VGPR=≥90% reduction from baseline serum; urine M-protein level 100mg for 24h. PR=≥50% reduction from baseline in serum M-protein; disappearance of any soft tissue plasmacytomas.","groups":[{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 45 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19","id":"OG000","title":"Dose Level 4 - Escalation and Expansion"},{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 56 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19","id":"OG001","title":"Dose Level 6 - Escalation and Expansion"}],"paramType":"NUMBER","populationDescription":"All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"up to 6 years","title":"Phase II: Overall Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}